tbuckley/cabot-search huggingface dataset:
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Authors: Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet-Loiseau, Michel Delforge, Thomas Dejoie, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon-Siong Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Jean Marc Schiano de Colella, Niels Wcj van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean-Pierre Marolleau, Nathalie Meuleman, Marie-Christiane Vekemans, Matthijs Westerman, Saskia K Klein, Mark-David Levin, Fritz Offner, Martine Escoffre-Barbe, Jean-Richard Eveillard, Réda Garidi, Winnie Hua, Jianping Wang, Alba Tuozzo, Carla de Boer, Melissa Rowe, Veronique Vanquickelberghe, Robin Carson, Jessica Vermeulen, Jill Corre, Pieter Sonneveld
Journal: The Lancet Oncology (2024)
Higher Resource Utilization And Mortality Among Patients With Heart Failure Admited With Diabetic Ketoacidosis And Chronic Kidney Disease
Authors: Kenan Rahima, Fayaz Khan, Mohamad Hijazi, Mhd Kutaiba Albuni, Amin Eshghabadi, Leonid Khoklov, Tochukwu Ikpeze
Journal: Metabolism (2024)
Effect of diet on insulin resistance in adults at risk of developing type 2 diabetes mellitus
Authors: Yethindra Vityala, Rithwik Goud Burri, Krishna Chaitanya Meduri, Sai Praneeth Duvvuri, Sriharsha Lankala, Annie Monica Ch, Raghu Ram Shanmukh Nemani, Tejaswi Vadde, Sai Prasad Karuturi, Harish Kumar Jella
Journal: Metabolism (2024)
Tirzepatide Improved Markers of Islet Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared to Semaglutide in People with Type 2 Diabetes
Authors: Katelyn Brown, Laura Fernandez Landó, Brandon Bergman, Melissa K. Thomas, Bing Liu, Clare Lee, Amanda M. Giebel
Journal: Metabolism (2024)
Inverse Relationship Between Creatinine-to-Body Weight (Cre/BW) Ratio and Incident Diabetes in a Multiethnic Cohort
Authors: Noraidatulakma Abdullah, Goh Ying Xian, Aisyatul Najihah Khuzaimi, Azwa Shawani Kamalul Arifin, Nurul Ain Mhd Yusuf, Nazihah Abd Jalal, Norliza Ismail, Nurul Faeizah Husin, Rahman Jamal
Journal: Metabolism (2024)
The association of insulin resistance and mild cognitive impairment in elderly patients with alzheimer's disease
Authors: Yethindra Vityala, Tugolbai Tagaev, Sai Kiran Ramanujam, Immi Harshitha Kalapala, Afreen Begum Kaggallu, Sameena Sultana, Gowtham Devara, Altynai Zhumabekova, Krishna Priya Kanteti, Ujwala Damineni
Journal: Metabolism (2024)
C3aR1 on beta cells preserves beta cell function and glucose homeostasis in diabetic mice by decreasing metabolic stress and dedifferentiation
Authors: Renan Lima, Ankit Gilani, Lisa Stoll, Eric Cortada, Edwin Homan, Kou Ang Li, Deanndria Singleton, Tint Tha Ra Wun, James C. Lo
Journal: Metabolism (2024)
Risk of Obesity, Diabetes, Insulin resistance, and Dyslipidemia among Irritable Bowel Syndrome patients
Authors: Yomna E. Dean, Jose Jonathan Loayza Pintado, Lucy L. Nale, Samah S. Rouzan, Ahmed Abbas, Mohamed Doma, Abdulla M. Aboushaira, Farah Alkasajy, Ahmed A. Ghanem, Vinayak Mahesh Patil, Yana Gordeyeva, Karam R. Motawea, Masako Lien Le, Adham Galal, Laura Cicani, Raneem Mohamed Atta, Sameh Samir Elawady, Lamya Alzabidi, Ahmed Soliman, Tamer Mady, Hani Aiash
Journal: Metabolism (2024)
Characterization of tirzepatide-treated patients achieving HbA1c &lt;5.7% in the SURPASS 1-4 trials
Authors: Julio Rosenstock, Stefano Del Prato, Denise Reis Franco, Luis Vázquez, Biyue Dai, Govinda Weerakkody, Laura Fernández-Landó, Angel Rodríguez, Brandon K. Bergman, Xi Chen
Journal: Metabolism (2024)
Diabetes, β cell apoptosis and the Role of SIRT2 and Rel/A NFkB subunit
Authors: Abdelmalek Rezgui, Rechda Amel Tachour, Rania Derguine, Anfel Benmanseur, Fatma Zahra Hab, Rym Agred, Hakim Rahmoune, Nada Boutrid, N. Baiben, A. Baiben, Widad SOBHI
Journal: Metabolism (2024)
Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis
Authors: Deepak L. Bhatt, Arun J. Sanyal, Stephen A. Harrison, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, Rohit Loomba
Journal: Metabolism (2024)
The Relationship Between Hypertension and Thoracic Spine Bone Mineral Density: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Ahmed K. Ghanem, Venkat S. Manubolu, April Kinninger, Robyn L. McClelland, Jaewon Lim, Denise Javier, Khadije Ahmad, Hossein Hamidi, Marziyeh Bagheri, Mina Deljavanghodrati, Matthew J. Budoff
Journal: Metabolism (2024)
Lower Serum Uric Acid Level in Patients with Gout Concurrent Type 2 Diabetes Mellitus Treated with Sodium-glucose Cotransporter 2 Inhibitors Compared to Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Cohort Study
Authors: Shu-Yen Chan, Pin-Chia Huang, Kevin Sheng-Kai
Journal: Metabolism (2024)
Effectiveness and Safety of an Adjuvant Phytoformula in the Treatment of Patients with Type 2 Diabetes Mellitus
Authors: Nidia Angélica García Espinoza, Hugo Morales Tello, Ricardo Sacchi Córdova, Nicasio Morales Sarabia, Jair Isaí Ortega Gaxiola, José Alfredo Primelles Gingele, María Magdalena Valencia Gutiérrez, Erick Ayala Calvillo, Cesar Ochoa Martinez
Journal: Metabolism (2024)
Sodium-dependent Glucose Transporter 2 Inhibitor Alleviates Renal Lipid Deposition and Improves Renal Oxygenation Levels in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial
Authors: Yunqi Wu, Li Zhang, Haizhen Sun, Guangyang Ma, Shan Lu, Saijun Zhou, Pei Yu
Journal: Metabolism (2024)
Pegozafermin Added to Background GLP-1 Therapy Led to Greater Improvement in Non-invasive Markers of Liver Fat, Injury and Fibrosis as well as Glycemic Control in NASH Patients with F2/F3 Fibrosis at 24 weeks: A Posthoc Analysis from ENLIVEN
Authors: Rohit Loomba, Arun J. Sanyal, Mildred D. Gottwald, Shibao Feng, Leo Tseng, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, Deepak L. Bhatt
Journal: Metabolism (2024)
Sotagliflozin Significantly Reduces CV Death and Heart Failure-related Outcomes in Patients with Type 2 Diabetes, Chronic Kidney Disease, and History of Heart Failure
Authors: M.B. Hardin, A.K. Carroll, M.J. Davies, M. Girard, P. Banks, B. Pitt, P.G. Steg, D.L. Bhatt
Journal: Metabolism (2024)
Association of EDARV370A with glycemic traits in Latinos residing in the Southwest
Authors: Carrie S. Standage-Beier, Yann C. Klimentidis, Luis A. Garcia, Oscar D. Parra, Lisa Soltani, Eleanna De Filippis, Gabriel Q. Shaibi, Douglas J. Spegman, Lawrence J. Mandarino, Dawn K. Coletta
Journal: Metabolism (2024)
Effect of Tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression (T-PLAQUE)
Authors: Hossein Hamidi, Marziyeh Bagheri, Jairo Aldana-Bitar, Denise A. Javier, Ahmed Ghanem, April Kinninger, Hooman Fazlalizade, Mina Deljavanghodrati, Sajad Hamal, Sina Kianoush, Matthew J. Budoff
Journal: Metabolism (2024)
Patients Admitted with Diabetic Ketoacidosis and a History of Non-alcoholic Fatty Liver Disease Have a Greater Risk of Mortality and Worse Clinical Outcomes
Authors: Kenan Rahima, Mohamad Hijazi, Mhd Kutaiba Albuni, Amin Eshghabadi, Leonid Khoklov, Tochukwu Ikpeze
Journal: Metabolism (2024)
Association Between G308A Polymorphism of TNF-α Gene and TNF-α levels, Insulin Resistance and Histological Alterations in Patients with NAFLD
Authors: Yethindra Vityala, Mahesh Palagudi, Sneha Para, Ravi Babu Kamma, Pavithra Kotha, Shravani Divity, Tugolbai Tagaev
Journal: Metabolism (2024)
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The <scp>ARES</scp> trial
Authors: Bianca Rocca, Alberto Tosetto, Giovanna Petrucci, Elena Rossi, Silvia Betti, Denise Soldati, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Rossella Renso, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandra Ricco, Giorgina Specchia, Alessandro M. Vannucchi, Francesco Rodeghiero, Valerio De Stefano, Carlo Patrono
Journal: American Journal of Hematology (2024)

Abstract Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily aspirin dosing restores persistent platelet thromboxane (TX) inhibition. However, the long‐term pharmacodynamic efficacy, safety and tolerability of twice‐daily aspirin remain untested. We performed a multicenter, randomized, open‐label, blinded‐endpoint, phase‐2 trial in which 242 patients with ET were randomized to 100 mg aspirin twice‐ or once‐daily and followed for 20 months. The primary endpoint was the persistence of low serum TXB 2 , a surrogate biomarker of antithrombotic efficacy. Secondary endpoints were major and clinically relevant non‐major bleedings, serious vascular events, symptom burden assessed by validated questionnaires, and in vivo platelet activation. Serum TXB 2 was consistently lower in the twice‐daily versus once‐daily regimen on 10 study visits over 20 months: median 3.9 ng/mL versus 19.2 ng/mL, respectively; p &lt; .001; 80% median reduction; 95% CI, 74%–85%. No major bleeding occurred. Clinically relevant non‐major bleedings were non‐significantly higher (6.6% vs. 1.7%), and major thromboses lower (0.8% vs. 2.5%) in the twice‐daily versus once‐daily group. Patients on the twice‐daily regimen had significantly lower frequencies of disease‐specific symptoms and severe hand and foot microvascular pain. Upper gastrointestinal pain was comparable in the two arms. In vivo platelet activation was significantly reduced by the twice‐daily regimen. In patients with ET, twice‐daily was persistently superior to once‐daily low‐dose aspirin in suppressing thromboxane biosynthesis and reducing symptom burden, with no detectable excess of bleeding and gastrointestinal discomfort.
Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression
Authors: Liya Ma, Kaiwen Zhang, Jian Xu, Jian Wang, Ting Jiang, Xiaolong Du, Jiaxin Zhang, Jing Huang, Fengyi Ren, Dong Liu, Weiwei Xue, Dongxu Kan, Mengjiao Yao, Yutian Liang, Hongxing Jason-Sun
Journal: Molecular Therapy (2024)

Despite the remarkable success of chimeric antigen receptor (CAR) T therapy in hematological malignancies, its efficacy in solid tumors remains limited. Cytokine-engineered CAR T cells offer a promising avenue, yet their clinical translation is hindered by the risks associated with constitutive cytokine expression. In this proof-of-concept study, we leverage the endogenous interferon (IFN)-γ promoter for transgenic interleukin (IL)-15 expression. We demonstrate that IFN-γ expression is tightly regulated by T cell receptor signaling. By introducing an internal ribosome entry site IL15 into the 3' UTR of the IFN-γ gene via homology directed repair-mediated knock-in, we confirm that IL-15 expression can co-express with IFN-γ in an antigen stimulation-dependent manner. Importantly, the insertion of transgenes does not compromise endogenous IFN-γ expression. In vitro and in vivo data demonstrate that IL-15 driven by the IFN-γ promoter dramatically improves CAR T cells' antitumor activity, suggesting the effectiveness of IL-15 expression. Last, as a part of our efforts toward clinical translation, we have developed an innovative two-gene knock-in approach. This approach enables the simultaneous integration of CAR and IL-15 genes into TRAC and IFN-γ gene loci using a single AAV vector. CAR T cells engineered to express IL-15 using this approach demonstrate enhanced antitumor efficacy. Overall, our study underscores the feasibility of utilizing endogenous promoters for transgenic cytokines expression in CAR T cells.
Hepatitis C virus diversity and treatment outcomes in Benin: a prospective cohort study
Authors: Lucrèce Ahovègbé, Rajiv Shah, Aboudou Raïmi Kpossou, Chris Davis, Marc Niebel, Ana Filipe, Emily Goldstein, Khadidjatou S Alassan, René Keke, Jean Sehonou, Nicolas Kodjoh, Sossa Edmond Gbedo, Surajit Ray, Craig Wilkie, Sreenu Vattipally, Lily Tong, Pakoyo F Kamba, S Judith Gbenoudon, Rory Gunson, Patrick Ogwang, Emma C Thomson
Journal: The Lancet Microbe (2024)
Author correction to “Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits” [Acta Pharm Sin B 14 (2024) 2732–2747]
Authors: Bo Xiao, Yuqi Liang, Ga Liu, Lingshuang Wang, Zhan Zhang, Libin Qiu, Haiting Xu, Sean Carr, Xiaoxiao Shi, Rui L. Reis, Subhas C. Kundu, Zhenhua Zhu
Journal: Acta Pharmaceutica Sinica B (2024)

[This corrects the article DOI: 10.1016/j.apsb.2024.02.008.].
Lost in translation: challenges of current pharmacotherapy for sarcopenia
Authors: Shih-Yin Tsai
Journal: Trends in Molecular Medicine (2024)

A healthy lifespan relies on independent living, in which active skeletal muscle is a critical element. The cost of not recognizing and acting earlier on unhealthy or aging muscle could be detrimental, since muscular weakness is inversely associated with all-cause mortality. Sarcopenia is characterized by a decline in skeletal muscle mass and strength and is associated with aging. Exercise is the only effective therapy to delay sarcopenia development and improve muscle health in older adults. Although numerous interventions have been proposed to reduce sarcopenia, none has yet succeeded in clinical trials. This review evaluates the biological gap between recent clinical trials targeting sarcopenia and the preclinical studies on which they are based, and suggests an alternative approach to bridge the discrepancy.
Multifunctional Adaptable Injectable TiN‐Based Hydrogels for Antitumor and Antidrug‐Resistant Bacterial Therapy
Authors: Jianghao Xing, Jie Shan, Haowei Xue, Hengguo Zhang, Liang Cheng, Jiqing Hao, Xianwen Wang
Journal: Advanced Healthcare Materials (2024)

The close relationship between bacteria and tumors has recently attracted increasing attention, and an increasing number of resources are being invested in the research and development of biomedical materials designed for the treatment of both. In this study, prefabricated TiN nanodots (NDs) and Fe(CO)
Anatomically plausible segmentations: Explicitly preserving topology through prior deformations
Authors: Madeleine K. Wyburd, Nicola K. Dinsdale, Mark Jenkinson, Ana I.L. Namburete
Journal: Medical Image Analysis (2024)

Since the rise of deep learning, new medical segmentation methods have rapidly been proposed with extremely promising results, often reporting marginal improvements on the previous state-of-the-art (SOTA) method. However, on visual inspection errors are often revealed, such as topological mistakes (e.g. holes or folds), that are not detected using traditional evaluation metrics. Incorrect topology can often lead to errors in clinically required downstream image processing tasks. Therefore, there is a need for new methods to focus on ensuring segmentations are topologically correct. In this work, we present TEDS-Net: a segmentation network that preserves anatomical topology whilst maintaining segmentation performance that is competitive with SOTA baselines. Further, we show how current SOTA segmentation methods can introduce problematic topological errors. TEDS-Net achieves anatomically plausible segmentation by using learnt topology-preserving fields to deform a prior. Traditionally, topology-preserving fields are described in the continuous domain and begin to break down when working in the discrete domain. Here, we introduce additional modifications that more strictly enforce topology preservation. We illustrate our method on an open-source medical heart dataset, performing both single and multi-structure segmentation, and show that the generated fields contain no folding voxels, which corresponds to full topology preservation on individual structures whilst vastly outperforming the other baselines on overall scene topology. The code is available at: https://github.com/mwyburd/TEDS-Net.
Dedifferentiation-like reprogramming of degenerative nucleus pulposus cells into notochordal-like cells by defined factors
Authors: Yuang Zhang, Chengzhen Liang, Haibin Xu, Yi Li, Kaishun Xia, Liyin Wang, Xianpeng Huang, Jiangjie Chen, Jiawei Shu, Feng Cheng, Kesi Shi, Jingkai Wang, Yiqing Tao, Shaoke Wang, Yongxiang Zhang, Hao Li, Shoumin Feng, Fangcai Li, Xiaopeng Zhou, Qixin Chen
Journal: Molecular Therapy (2024)

The extensive degeneration of functional somatic cells and the depletion of endogenous stem/progenitor populations present significant challenges to tissue regeneration in degenerative diseases. Currently, a cellular reprogramming approach enabling directly generating corresponding progenitor populations from degenerative somatic cells remains elusive. The present study focused on intervertebral disc degeneration (IVDD) and identified a three-factor combination (OCT4, FOXA2, TBXT (OFT)) that could induce the dedifferentiation-like reprogramming of degenerative nucleus pulposus cells (dNPCs) toward induced notochordal-like cells (iNCs). Single-cell transcriptomics dissected the transitions of cell identity during reprogramming. Further, OCT4 was found to directly interact with bromodomain PHD-finger transcription factor (BPTF) to remodel the chromatin during the early phases, which was crucial for initiating this dedifferentiation-like reprogramming. In rat models, intradiscal injection of adeno-associated virus carrying OFT generated iNCs from in situ dNPCs and reversed IVDD. These results collectively present a proof-of-concept for dedifferentiation-like reprogramming of degenerated somatic cells into corresponding progenitors through the development of a factor-based strategy, providing a promising approach for regeneration in degenerative disc diseases. The extensive degeneration of functional somatic cells and the depletion of endogenous stem/progenitor populations present significant challenges to tissue regeneration in degenerative diseases. Currently, a cellular reprogramming approach enabling directly generating corresponding progenitor populations from degenerative somatic cells remains elusive. The present study focused on intervertebral disc degeneration (IVDD) and identified a three-factor combination (OCT4, FOXA2, TBXT (OFT)) that could induce the dedifferentiation-like reprogramming of degenerative nucleus pulposus cells (dNPCs) toward induced notochordal-like cells (iNCs). Single-cell transcriptomics dissected the transitions of cell identity during reprogramming. Further, OCT4 was found to directly interact with bromodomain PHD-finger transcription factor (BPTF) to remodel the chromatin during the early phases, which was crucial for initiating this dedifferentiation-like reprogramming. In rat models, intradiscal injection of adeno-associated virus carrying OFT generated iNCs from in situ dNPCs and reversed IVDD. These results collectively present a proof-of-concept for dedifferentiation-like reprogramming of degenerated somatic cells into corresponding progenitors through the development of a factor-based strategy, providing a promising approach for regeneration in degenerative disc diseases.
Takayasu arteritis-associated periostitis in the distal femur mimicking periosteal osteosarcoma
Authors: Mariko M Kawamura, Robert Nakayama, Sayaka I Yamaguchi, Satoshi Kamio, Toru Hirozane, Tomoaki Mori, Naofumi Asano, Hajime Okita, Morio Matsumoto, Masaya Nakamura
Journal: The Lancet Rheumatology (2024)
Bioceramic-mediated chondrocyte hypertrophy promotes calcified cartilage formation for rabbit osteochondral defect repair
Authors: Rachel H Koh, Junhee Kim, Jeong-Uk Kim, Seunghyun L Kim, Arun Kumar Rajendran, Seunghun S Lee, Heesoo Lee, Joo Hyun Kim, Ji Hoon Jeong, Yongsung Hwang, Jong Woo Bae, Nathaniel S Hwang
Journal: Bioactive Materials (2024)
Interpretable deep clustering survival machines for Alzheimer’s disease subtype discovery
Authors: Bojian Hou, Zixuan Wen, Jingxuan Bao, Richard Zhang, Boning Tong, Shu Yang, Junhao Wen, Yuhan Cui, Jason H. Moore, Andrew J. Saykin, Heng Huang, Paul M. Thompson, Marylyn D. Ritchie, Christos Davatzikos, Li Shen
Journal: Medical Image Analysis (2024)
A review of the literature on wellbeing and modifiable dementia risk factors
Authors: Emily C. Willroth, Gabrielle N. Pfund, Payton D. Rule, Patrick L. Hill, Amber John, Kalista Kyle, Jason Hassenstab, Bryan D. James
Journal: Ageing Research Reviews (2024)

Wellbeing—defined broadly as experiencing one's life as enjoyable and fulfilling—has been associated with lower risk for Alzheimer's disease and related dementias. The mechanisms underlying this association are largely unknown. However, prior research and theory suggest that wellbeing impacts health behaviors and biological systems that are relevant to cognitive and brain health. Several of these factors have also been identified by the 2020 Lancet Commission on Dementia Prevention, Intervention, and Care as modifiable dementia risk factors. In the current review, we summarize and evaluate the evidence for associations between wellbeing and each of the 12 Lancet Commission risk factors. We found relatively consistent evidence for associations between higher wellbeing and lower levels of most of the risk factors: physical inactivity, social isolation, smoking, depression, hypertension, diabetes, hearing loss, traumatic brain injury, and air pollution. By contrast, we found evidence for only modest associations between wellbeing and education and mixed evidence for associations of wellbeing with alcohol use and body weight. Although most of the reviewed evidence was observational, longitudinal and experimental evidence suggests that many of the observed associations are likely bidirectional. These findings suggest that modifiable dementia risk factors may be mediators (i.e., intermediate steps in the causal chain) and/or confounders (i.e., variables that impact both wellbeing and dementia, and thus could induce a spurious association) of the association between wellbeing and dementia. We conclude by discussing next steps to test mediation hypotheses and to account for potential confounding in the relation between wellbeing and dementia.
Sequential SAFE Score and Transient Elastography for Detecting Significant Fibrosis in Asian Patients with MASLD
Authors: Apichat Kaewdech, Pimsiri Sripongpun, Sombat Treeprasertsuk, Phunchai Charatcharoenwitthaya, Wah Kheong Chan, Naichaya Chamroonkul, Cheng Han Ng, Mark Dhinesh Muthiah, Yock Young Dan, W. Ray Kim
Journal: Clinical Gastroenterology and Hepatology (2024)
Nasal brushing molecular endotyping distinguishes patients with chronic rhinosinusitis with nasal polyps with better response to dupilumab
Authors: Kaitlyn Gayvert, Martin Desrosiers, Tanya M Laidlaw, Leda P Mannent, Kiran Patel, Julie Horowitz, Nikhil Amin, Alexandre Jagerschmidt, Jennifer D Hamilton, Wei Keat Lim, Sivan Harel
Journal: Journal of Allergy and Clinical Immunology (2024)

There is evidence of pathophysiologic diversity in chronic rhinosinusitis with nasal polyps (CRSwNP), but data characterizing the molecular endotypes of CRSwNP and their association with treatment are lacking.